This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Varian Expands Access to Advanced Cancer Treatment With Ethos
by Zacks Equity Research
Varian's (VAR) Ethos Therapy used by Goshen Center for Cancer Care marks the expansion access to personalized cancer care.
PRA Health (PRAH) Inks Deal With Leukemia & Lymphoma Society
by Zacks Equity Research
PRA Health (PRAH) partners with LLS to bring new treatments for children with relapsed acute leukemia.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) continues to gain traction from Senza, its flagship platform, and R&D capabilities. However, stiff competition remains a woe.
Varian's Halcyon System to Bring Improved Care to Singapore
by Zacks Equity Research
Varian (VAR) strengthens its partnership Proton Therapy Pte as it brings improved care to Singapore through Halcyon system.
NextGen Healthcare Introduces New Behavioral Health Suite
by Zacks Equity Research
NextGen Healthcare's (NXGN) new behavioral health suite aims to provide whole person care with support services for healthcare providers and clinicians.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter earnings reflect dismal segmental performance. However, it exceeded expectation as it witnessed faster-than-anticipated recovery.
Top Ranked Growth Stocks to Buy for September 4th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, September 4th.
Aurora Cannabis (ACB) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal fourth-quarter results likely to reflect solid prospects in the Canadian market.
Patterson Companies (PDCO) Q1 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Despite weak performance across Patterson Companies' (PDCO) Dental and Animal Health segments in the fiscal first quarter results, it benefited from aggressive cost savings measures.
Zacks.com featured highlights include: Kinsale Capital, American States Water, Gibraltar Industries, D.R. Horton and West Pharmaceutical
by Zacks Equity Research
Zacks.com featured highlights include: Kinsale Capital, American States Water, Gibraltar Industries, D.R. Horton and West Pharmaceutical
Buy These 5 Low Leverage Stocks Amid Ongoing Economic Crisis
by Aparajita Dutta
As the global economy is still topsy turvy, thanks to the coronavirus pandemic, investors should be even more careful while choosing stocks
What's in Store for Patterson Companies' (PDCO) Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect sluggishness at Dental segment.
Here's Why You Should Invest in LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter performance is likely to reflect weak performance by CVI and CSI.
Is West Pharmaceutical Services (WST) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
Hologic Updates Breast Biopsy System to Enhance Workflow
by Zacks Equity Research
Hologic (HOLX) introduces features to update Brevera Breast Biopsy System in order to transform patient experience and enhance workflow.
Phibro (PAHC) Q4 Earnings Fall Short of Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment was aided by the Osprey Biotechnics acquisition despite a dismal overall performance in Q4 due to pandemic-led business disruptions.
AMN Healthcare's Advanced Mobile App to Aid Travel Clinicians
by Zacks Equity Research
AMN Healthcare's (AMN) new version of AMN Passport will benefit travel clinicians.
Allscripts Enhances Healthcare Innovation With Patent Program
by Zacks Equity Research
Allscripts (MDRX) continues to advance healthcare innovation by earning five new application patents.
Here's Why You Should Hold on to DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY (XRAY) continues to gain traction from its solid focus on R&D leading to product innovation, which continues to be a key catalyst.
Here's Why You Should Invest in Fresenius Medical Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services.
Veeva Systems (VEEV) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal second-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Buy These 5 Low Leverage Stocks to Weather Coronavirus Impact
by Aparajita Dutta
With the Q2 reporting cycle drawing to a close, investors must be eyeing stocks that exhibited solid earnings growth in the prior quarters. But choosing stocks with high debt level might be risky.
Allscripts' Collaboration to Advance Healthcare Innovation
by Zacks Equity Research
Allscripts (MDRX) partners with Israel's Sheba Medical Center to help enhance healthcare innovation with smarter technology, thereby improving patient outcomes.